
    
      The study will evaluate safety and efficacy in participant with small cell lung cancer,
      urothelial cancer and bladder cancer who have developed resistance to prior anti-PD1 or
      anti-PD-L1 therapy and in patient with cholangiocarcinoma who have received at least 1 line
      of standard of care therapy and have progressed on it.

      Per 22nd of December 2020 recruitment for small cell lung cancer, urothelial cancer and
      bladder cancer has temporarily stopped due to strategy considerations. Recruitment for
      cholangiocarcinoma is still open.
    
  